R. Katherine Hyde

1.2k total citations
30 papers, 562 citations indexed

About

R. Katherine Hyde is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, R. Katherine Hyde has authored 30 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 17 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in R. Katherine Hyde's work include Acute Myeloid Leukemia Research (19 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). R. Katherine Hyde is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). R. Katherine Hyde collaborates with scholars based in United States, United Kingdom and Canada. R. Katherine Hyde's co-authors include Lemlem Alemu, Ling Zhao, Peiqing Liu, Anne E. Griep, Paul Liu, Yiqian Wang, Lijuan Zhao, Yasuhiko Kamikubo, Scott Balsitis and Denis Lee and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

R. Katherine Hyde

30 papers receiving 558 citations

Peers

R. Katherine Hyde

HEMAT

ONCOL

IMMUN

Shaina N. Porter United States

Talía Velasco-Hernández Spain

Marzia Vezzalini Italy

Junji Koya Japan

Melissa L. Abel United States

Tamara Tripic United States

Qing Tong China

Carl‐Magnus Högerkorp Sweden

Joshua S. Hardin United States

Boris Brill Germany

Shaina N. Porter United States

R. Katherine Hyde

597 ×1.7

108 ×0.5

HEMAT

93 ×0.9

ONCOL

181 ×1.9

IMMUN

71 ×1.2

Citations per year, relative to R. Katherine Hyde R. Katherine Hyde (= 1×) peers Shaina N. Porter

Countries citing papers authored by R. Katherine Hyde

Since Specialization

Citations

This map shows the geographic impact of R. Katherine Hyde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Katherine Hyde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Katherine Hyde more than expected).

Fields of papers citing papers by R. Katherine Hyde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Katherine Hyde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Katherine Hyde. The network helps show where R. Katherine Hyde may publish in the future.

Co-authorship network of co-authors of R. Katherine Hyde

This figure shows the co-authorship network connecting the top 25 collaborators of R. Katherine Hyde. A scholar is included among the top collaborators of R. Katherine Hyde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Katherine Hyde. R. Katherine Hyde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xin, Xiaofei, Yuxiang Dong, Virender Kumar, et al.. (2024). Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia. Molecular Therapy. 32(11). 4058–4074. 4 indexed citations

Swenson, Samantha, et al.. (2023). FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia. Leukemia. 37(11). 2197–2208. 2 indexed citations

Hyde, R. Katherine, et al.. (2022). Synthetic Immunotherapy: Programming Immune Cells with Novel and Sophisticated Logic Capabilities. Transplantation and Cellular Therapy. 28(9). 560–571. 5 indexed citations

Bhatt, Vijaya Raj, Christopher Wichman, Zaid Al‐Kadhimi, et al.. (2022). Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. Journal of Geriatric Oncology. 13(6). 871–874. 15 indexed citations

Zhen, Tao, Yaqiang Cao, Gang Ren, et al.. (2020). RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development. Blood. 136(21). 2373–2385. 22 indexed citations

Wang, Yiqian, et al.. (2020). IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia. Leukemia Research. 96. 106409–106409. 10 indexed citations

Wang, Yiqian, et al.. (2019). HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia. Molecular Cancer Research. 17(6). 1241–1252. 14 indexed citations

Wang, Yiqian, et al.. (2019). IL1RL1 is dynamically expressed on Cbfb-MYH11+ leukemia stem cells and promotes cell survival. Scientific Reports. 9(1). 1729–1729. 15 indexed citations

Wang, Yiqian, Ying Xie, Hang Yu, et al.. (2019). Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia. Cancer Gene Therapy. 27(1-2). 45–55. 17 indexed citations

10.

Zhen, Tao, Erika M. Kwon, Ling Zhao, et al.. (2017). Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. Blood. 130(22). 2431–2442. 20 indexed citations

11.

Hyde, R. Katherine, Paul Liu, & Alan D. Friedman. (2017). RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML. Advances in experimental medicine and biology. 962. 265–282. 9 indexed citations

12.

Wang, Yiqian, et al.. (2016). Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia. Oncotarget. 7(40). 66255–66266. 7 indexed citations

13.

Hyde, R. Katherine, et al.. (2015). Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice. Leukemia. 29(8). 1771–1778. 36 indexed citations

14.

Davies, Michael P.A., Orna Barash, Raneen Jeries, et al.. (2014). Unique volatolomic signatures of TP53 and KRAS in lung cells. British Journal of Cancer. 111(6). 1213–1221. 38 indexed citations

15.

Bediaga, Naiara G., Michael P.A. Davies, Amelia Acha‐Sagredo, et al.. (2013). A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. British Journal of Cancer. 109(9). 2404–2411. 27 indexed citations

16.

Kamikubo, Yasuhiko, R. Katherine Hyde, Ling Zhao, et al.. (2012). The C-terminus of CBFβ-SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis. Blood. 121(4). 638–642. 11 indexed citations

17.

Hyde, R. Katherine & Peiqing Liu. (2010). RUNX1 repression‐independent mechanisms of leukemogenesis by fusion genes CBFB–MYH11 and AML1–ETO (RUNX1–RUNX1T1). Journal of Cellular Biochemistry. 110(5). 1039–1045. 14 indexed citations

18.

Kamikubo, Yasuhiko, Ling Zhao, Mark Wunderlich, et al.. (2010). Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1. Cancer Cell. 17(5). 455–468. 34 indexed citations

19.

Hyde, R. Katherine, et al.. (2010). The role of microRNAs in acute myeloid leukemia. F1000 Biology Reports. 2. 81–81. 3 indexed citations

20.

Khan, Anzalee, R. Katherine Hyde, Amalia Dutra, Patrick Mohide, & Paul Liu. (2006). Core binding factor beta (CBFB) haploinsufficiency due to an interstitial deletion at 16q21q22 resulting in delayed cranial ossification, cleft palate, congenital heart anomalies, and feeding difficulties but favorable outcome. American Journal of Medical Genetics Part A. 140A(21). 2349–2354. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact